2024 CSL Research Acceleration Initiative – Partnership opportunity on innovative biotherapies research

CSL is a global biotechnology company with headquarter in Australia that develops and delivers innovative biotherapies. The company’s Research Acceleration Initiative (RAI) aims to explore partnerships on novel biotherapeutic strategies in CSL’s therapeutic areas, with funding up to USD400,000 over 2 years.

2024 CSL Research Acceleration Initiative: Call for Proposals

The 2024 RAI focuses on the therapeutic areas including modalities, antibodies recombinant proteins and LV gene therapies cell therapies, etc. Researchers who wish to apply are required to submit a non-confidential, 300 word abstract by 22 February 2024 5pm HKT to Research and Innovation Office (RIO). 

Interested researchers are invited to attend information webinars to learn more about the initiative at a time slot that best fits for you.  More details and the links to webinars can be found on the Global RAI 2024 Scientific Flyer.

• 2^nd February 11:00 am HKT (2:00 pm AEDT) or
• 5^th  February 11:00 am HKT (2:00 pm AEDT)

(Researchers need only attend one of the webinars as the two sessions are parallel.)